XT
ACRV icon

XTX Topco’s Acrivon Therapeutics ACRV Stock Holding History

XTX Topco’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$93K Buy
66,882
+46,310
+225% +$80.8K ﹤0.01% 3129
2025
Q4 		$49.6K Sell
20,572
-15,383
-43% -$33.4K ﹤0.01% 2837
2025
Q3 		$65.1K Sell
35,955
-70,164
-66% -$98.6K ﹤0.01% 2111
2025
Q2 		$126K Buy
+106,119
New +$146K 0.01% 1831
2024
Q3 		– Sell
-10,493
Closed -$60.9K – 2027
2024
Q2 		$60.9K Buy
+10,493
New +$84.5K 0.01% 1487

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

XTX Topco's ACRV Position: Q1 2026 in Review

XTX Topco increased its Acrivon Therapeutics (ACRV) stake by 225% in Q1 2026, buying an estimated $80.8K and bringing the position to 66,882 shares worth $93K. The position accounts for ﹤0.01% of the portfolio, ranked #3129.

XTX Topco first reported a position in ACRV in Q2 2024 and has held it in 5 quarters since. The position peaked at $126K in Q2 2025. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

  • XTX Topco held 66,882 shares of Acrivon Therapeutics worth $93K as of Q1 2026.
  • XTX Topco bought 46,310 Acrivon Therapeutics shares in Q1 2026, an estimated $80.8K.
  • Acrivon Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q1 2026, its #3129 holding.
  • XTX Topco first reported a position in Acrivon Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • XTX Topco's Acrivon Therapeutics position peaked at $126K in Q2 2025.
  • 44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.